Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared on X:
“Medicare’s 2027 outpatient rule could lower patients’ drug bills – but also changes incentives for hospitals and cancer practices. A short thread on 340B, site-neutral payments and access to care.
CMS will pay for qualifying 340B-acquired outpatient drugs at ASP.
- 28%. It projects $1.1B less in beneficiary drug payments in 2027, and
- ~$900 in average savings for a beneficiary receiving a qualifying drug in a hospital outpatient department.
Critical nuance: the 340B change is budget neutral within Medicare’s hospital outpatient payment system.
Lower drug reimbursements are offset by higher payments for non-drug outpatient services. Not $4.35B in net savings across those services.
CMS also extends site-neutral reimbursement to certain imaging without contrast in off-campus hospital departments. The same scan should not automatically cost more because a hospital owns the facility.
CMS projects ~$260M in first-year Part B expenditure reductions.
The test: out-of-pocket costs, safety-net access, independent-practice viability and consolidation. Payment reforms shape incentives – not just prices.
Lower costs matter, but so do quality and access.
You can also read:
